Clinical and cytogenetic characteristics of Ph− ALL patients
| Patient sample . | Subtype . | Sample type . | Additional cytogenetic abnormality . | Cytogenetic . | WBC, ×109/L . | Blast % in PB . | Blast % in BM . |
|---|---|---|---|---|---|---|---|
| 1 | Pre-B | PB | N | Female karyotype | 28.7 | 90.0 | 95.0 |
| 2 | Pre-T | PB | Y | TP15/TP16/9p21, 86% by FISH | 109.3 | 82.0 | 100.0 |
| 3 | Pre-B | BM | Y | Tetrasomy 9/22, 10.3% by FISH | 4.1 | 4.0 | 80.0 |
| 4* | Pre-T | BM | Y | Add(1);t(10;11), 13/20 | 1.2 | 18.0 | 98.0 |
| 5 | Pre-B | BM | Y | Trisomy 11, 5.0% by FISH; trisomy 22, 4.6% by FISH | 1.9 | 10.0 | 68.0 |
| 6 | Pre-B | BM | Y | Trisomy 22 | 75.3 | 96.0 | 89.0 |
| Patient sample . | Subtype . | Sample type . | Additional cytogenetic abnormality . | Cytogenetic . | WBC, ×109/L . | Blast % in PB . | Blast % in BM . |
|---|---|---|---|---|---|---|---|
| 1 | Pre-B | PB | N | Female karyotype | 28.7 | 90.0 | 95.0 |
| 2 | Pre-T | PB | Y | TP15/TP16/9p21, 86% by FISH | 109.3 | 82.0 | 100.0 |
| 3 | Pre-B | BM | Y | Tetrasomy 9/22, 10.3% by FISH | 4.1 | 4.0 | 80.0 |
| 4* | Pre-T | BM | Y | Add(1);t(10;11), 13/20 | 1.2 | 18.0 | 98.0 |
| 5 | Pre-B | BM | Y | Trisomy 11, 5.0% by FISH; trisomy 22, 4.6% by FISH | 1.9 | 10.0 | 68.0 |
| 6 | Pre-B | BM | Y | Trisomy 22 | 75.3 | 96.0 | 89.0 |
FISH indicates fluorescent in situ hybridization.
Relapsed patient.